Peripheral CEA-specific T-cell responses predict anti-PD-1 outcomes in dMMR/MSI-H colorectal cancer

Assessment of CEA-specific T-cell responses may provide clinically relevant information for predicting treatment response and prognosis in colorectal cancer, but clinical translation has been hindered by incomplete epitope mapping and the lack of standardized, broadly applicable immune-monitoring assays. CD8 + T-cell epitopes in CEA were systematically screened using in silico prediction, peptide-PBMC co-culture, competitive binding assays, and HLA-transgenic mouse immunization. Validated epitopes were used to establish an IFN-γ ELISpot assay for quantifying CEA-specific T-cell responses in dMMR/MSI-H CRC patients receiving anti-PD-1 therapy, including a derivation cohort ( n = 80) and an independent test cohort ( n = 21), with objective response and 12 month PFS as clinical endpoints. We validated 59 immunogenic CD8 + T-cell epitopes restricted by 13 HLA-A, 15 HLA-B, and 14 HLA-C allotypes and covering > 90%, 70%, and 90% of Northeast Asian populations, respectively. In the derivation cohort, the post-/pre-treatment CEA-specific T-cell fold predicted objective response (AUC = 0.866; cut-off = 2.15) and 12 month PFS (AUC = 0.851; cut-off = 2.05), outperforming KRAS/BRAF status and early serum CEA decline. Based on these cut-offs, a unified fold cut-off of 2.1 was predefined for validation and retained predictive performance in the independent test cohort, with AUCs of 0.809 and 0.824 for objective response and 12 month PFS, respectively. We established an ELISpot assay to quantify CEA-specific T-cell responses and found that this peripheral blood readout may serve as a clinically informative biomarker for stratifying response and PFS after anti-PD-1 therapy in dMMR/MSI-H CRC.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2026-11-18
DOI
https://doi.org/10.1007/s00262-026-04633-3
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Peripheral CEA-specific T-cell responses predict anti-PD-1 outcomes in dMMR/MSI-H colorectal cancer

沈传来, Zhang Xuan, Wei Liu, Haixiao Fu et al.
Cancer Immunology Immunotherapy
Cancer Immunotherapy and Biomarkers
article

Peripheral CEA-specific T-cell responses predict anti-PD-1 outcomes in dMMR/MSI-H colorectal cancer

沈传来, Zhang Xuan, Wei Liu, Haixiao Fu, Suyue Zhu
article en

Abstract

Assessment of CEA-specific T-cell responses may provide clinically relevant information for predicting treatment response and prognosis in colorectal cancer, but clinical translation has been hindered by incomplete epitope mapping and the lack of standardized, broadly applicable immune-monitoring assays. CD8 + T-cell epitopes in CEA were systematically screened using in silico prediction, peptide-PBMC co-culture, competitive binding assays, and HLA-transgenic mouse immunization. Validated epitopes were used to establish an IFN-γ ELISpot assay for quantifying CEA-specific T-cell responses in dMMR/MSI-H CRC patients receiving anti-PD-1 therapy, including a derivation cohort ( n = 80) and an independent test cohort ( n = 21), with objective response and 12 month PFS as clinical endpoints. We validated 59 immunogenic CD8 + T-cell epitopes restricted by 13 HLA-A, 15 HLA-B, and 14 HLA-C allotypes and covering > 90%, 70%, and 90% of Northeast Asian populations, respectively. In the derivation cohort, the post-/pre-treatment CEA-specific T-cell fold predicted objective response (AUC = 0.866; cut-off = 2.15) and 12 month PFS (AUC = 0.851; cut-off = 2.05), outperforming KRAS/BRAF status and early serum CEA decline. Based on these cut-offs, a unified fold cut-off of 2.1 was predefined for validation and retained predictive performance in the independent test cohort, with AUCs of 0.809 and 0.824 for objective response and 12 month PFS, respectively. We established an ELISpot assay to quantify CEA-specific T-cell responses and found that this peripheral blood readout may serve as a clinically informative biomarker for stratifying response and PFS after anti-PD-1 therapy in dMMR/MSI-H CRC.

Cancer Immunology Immunotherapy
Xuzhou Medical College (CN), Southeast University (CN)
National Natural Science Foundation of China, Xuzhou Medical University
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon